Claim OwnershipResearch To Practice | Oncology Videos
Subscribed: 595Played: 40,985
Subscribe
Copyright © 2023 Research To Practice. All Rights Reserved.
Description
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
851 Episodes
Reverse
Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics: Introduction (0:00) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25) Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54) Tolerability and Other Practical Considerations with Capivasertib — Dr Heath (1:03:15) CME information and select publications
Featuring perspectives from Ms Jamie Carroll, Prof Giuseppe Curigliano, Dr Marie E McDonnell and Dr Hope S Rugo, including the following topics: Introduction: Use of On-Body Glucose Monitoring Devices (0:00) Overview of Breast Cancer and Diabetes (9:39) PI3K/AKT/mTOR Pathway and Glucose Metabolism (19:28) Case Presentations — Part 1 (26:02) Current Data with Alpelisib, Capivasertib and Inavolisib (43:51) Prevention and Management of Hyperglycemia (1:02:17) Case Presentations — Part 2 (1:10:24) CME information and select publications
Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics: Case: A man in his mid 50s with metastatic recurrence of urothelial bladder cancer (UBC) after neoadjuvant cisplatin/gemcitabine receives first-line enfortumab vedotin (EV)/pembrolizumab (0:00) Case: A man in his early 50s with muscle-invasive bladder cancer (MIBC) receives adjuvant pembrolizumab, experiences disease progression and then receives EV monotherapy (12:33) Case: A man in his late 80s with recurrent metastatic UBC after pembrolizumab therapy for MIBC receives EV monotherapy at a reduced dose (24:07) CME information and select publications
Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Neoadjuvant immunotherapy for localized rectal cancer (0:00) Surveillance in neoadjuvant immunotherapy for localized rectal cancer (8:14) Determining a treatment strategy for resectable colon cancer (12:35) CME information and select publications
Featuring perspectives from Dr Matthew D Galsky, Dr Shilpa Gupta, Dr Terence Friedlander and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Introduction (0:00) Optimal Use of Anti-PD-1/PD-L1 Antibodies in Non-Muscle-Invasive Bladder Cancer — Dr Friedlander (2:27) Evolving Management of Muscle-Invasive Bladder Cancer — Dr Gupta (33:30) Current and Future Role of Novel Intravesical Therapies in Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (1:01:56) Emerging Utility of Circulating Tumor DNA Evaluation in Nonmetastatic UBC — Dr Galsky (1:32:47) CME information and select publications
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Younger patient with metastatic HER2-positive, PD-L1-positive gastric cancer (0:00) Older patient with metastatic HER2-positive gastroesophageal (GE) cancer (8:13) Clinical applications for zanidatamab in GE cancer (13:58) CME information and select publications
Featuring perspectives from Dr Paul G Richardson, including the following topics: Mechanism of action and pharmacology of cereblon E3 ligase modulators (0:00) Available efficacy data (4:54) Extramedullary disease (10:51) Side effects and toxicity (16:58) CME information and select publications
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Case: A woman in her early 70s incidentally diagnosed with immune thrombocytopenia (ITP) experiences a suboptimal response to prednisone and IVIG — Bhavana (Tina) Bhatnagar, DO (0:00) Case: A man in his early 50s with a long history of ITP undergoes splenectomy — Neil Morganstein, MD (5:06) Case: A woman in her mid 50s with symptomatic iron-deficiency anemia who was found to have ITP has received corticosteroids, rituximab and IVIG — Jennifer Yannucci, MD (12:25) Case: A woman in her early 30s who previously received ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and autologous stem cell transplant for Hodgkin lymphoma is diagnosed with ITP 5 years later that is refractory to high-dose prednisone, IVIG and rituximab, then romiplostim — Priya Rudolph, MD, PhD (18:19) CME information and select publications
Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Novel immune checkpoint inhibitors (0:00) Gastroesophageal junction cancer (7:36) Gastric cancer (14:52) CME information and select publications
Featuring an interview with Dr Lajos Pusztai, including the following topics: Circulating tumor DNA monitoring for patients with ER-positive, HER2-negative high-risk breast cancer during adjuvant endocrine therapy (0:00) Clinical performance of a whole-genome assay for predicting disease recurrence (5:52) Using circulating tumor DNA status to personalize CDK4/6 inhibitor therapy (12:46) Neoadjuvant and adjuvant therapy stratified by circulating tumor DNA status (21:11) Utility of circulating tumor DNA status in the management of metastatic breast cancer (24:55) CME information and select publications
Featuring an interview with Dr Ravin Ratan, including the following topics: Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors: Results from the Phase III DeFi trial (0:00) Onset and resolution of ovarian toxicity with nirogacestat treatment for desmoid tumors: Updated safety analyses from the DeFi trial (4:37) Subgroup analysis of the Phase II part of the RINGSIDE Phase II/III trial of varegacestat for desmoid tumors (7:39) Surgical management of desmoid tumors; cryotherapy in the treatment of extra-abdominal desmoid tumors (10:30) CME information and select publications
Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Biliary tract cancer progressing on first-line therapy (0:00) Gallbladder cancer (5:01) Biliary tract cancer with multiple biomarker targets (8:52) CME information and select publications
Featuring an interview with Dr Bijal Shah, including the following topics: Advent and importance of blinatumomab in the therapeutic landscape of acute lymphoblastic leukemia (ALL) (0:00) Similarities and differences between bispecific T-cell engagers (BiTEs) and bispecific antibodies (5:51) Rationale underlying the development of surovatamig and MK-1045; benefits of blinatumomab for patients without detectable minimal residual disease (9:56) Extramedullary ALL, including in the CNS (13:32) Key principles in the development and use of surovatamig and MK-1045, including structural features and recent efficacy and safety findings (18:34) Ongoing immunotherapy trials for ALL, including studies of BiTEs and chimeric antigen receptor T-cell therapy (25:37) Case: A woman in her late 50s with newly diagnosed Philadelphia chromosome-positive B-cell ALL and multiple comorbidities (31:48) Case: A woman in her early 50s with newly diagnosed B-cell ALL, a TP53 mutation and significant extramedullary disease including the CNS (41:16) Case: A man in his early 50s with intermediate-risk B-cell ALL who receives surovatamig on a clinical trial (53:05) CME information and select publications
Featuring a slide presentation and related discussion from Dr Bijal Shah, including the following topics: Historical approaches to managing acute lymphoblastic leukemia, their limitations and present approaches to treatment (0:00) Mechanistic approach underlying blinatumomab; key clinical trial data and their implications (7:29) Mechanistic approaches underlying surovatamig and MK-1045; dosing and administration strategies with various bispecific T-cell engagers (23:27) Key clinical trial data with surovatamig; implications for practice (32:38) Key clinical trial data with MK-1045; implications for practice (39:02) Synthesizing and comparing data across subcutaneous blinatumomab, surovatamig and MK-1045 (42:36) CME information and select publications
Featuring an interview with Prof Constantine Tam, including the following topics: Evolving first-line treatment paradigm for patients with previously untreated chronic lymphocytic leukemia (CLL) (0:00) Considerations for the administration of first-line venetoclax-based regimens (3:24) Mechanism of action of sonrotoclax and observed early-phase efficacy in combination with zanubrutinib; minimal residual disease as a potential clinical trial endpoint (10:01) Continuous versus fixed-duration first-line treatment approaches for previously untreated CLL (14:38) Selecting between up-front acalabrutinib- and zanubrutinib-based time-limited therapy options (19:07) Up-front treatment selection for patients with del(17p) CLL (24:01) Stopping and restarting acalabrutinib for frail patients with previously untreated CLL (26:43) Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (30:20) Lisocabtagene maraleucel as treatment for patients with double-refractory CLL (37:00) Perspectives on future roles of novel therapies and treatment strategies (43:11) CME information and select publications
Featuring a slide presentation and related discussion from Prof Constantine Tam, including the following topics: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL): Results from the randomized CLL17 trial (0:00) Six-year follow-up data from the Phase III SEQUOIA trial of zanubrutinib for patients with treatment-naïve CLL and those with del(17p) CLL not randomly assigned (4:59) Primary endpoint analysis of the randomized STAIR trial of time-limited acalabrutinib monotherapy for frail patients with previously untreated CLL (7:25) Safety analyses of acalabrutinib/venetoclax (AV) or AV in combination with obinutuzumab for previously untreated CLL (10:50) Three-year results with zanubrutinib combined with venetoclax in arm D of the Phase III SEQUOIA trial for treatment-naïve CLL (17:15) Early-phase data with sonrotoclax combinations as front-line treatment of CLL (19:12) Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (23:27) Long-term extension (LTE1) results from the Phase III ALPINE trial of zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL or small lymphocytic lymphoma (R/R CLL/SLL) (28:53) Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with R/R CLL/SLL from the ongoing phase 1 CaDAnCe-101 study (30:35) Real-world outcomes of lisocabtagene maraleucel in CLL (33:04) CME information and select publications
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: VAYHIT1: A multicenter randomized, double-blind, Phase III trial evaluating ianalumab versus placebo in addition to first-line corticosteroids for patients with primary immune thrombocytopenia (ITP) (0:00) Secondary analysis results from VAYHIT3, a Phase II study of ianalumab for patients with primary ITP previously treated with at least 2 lines of therapy (8:15) Improved health-related quality of life and bleeding scores with the oral Bruton tyrosine kinase inhibitor rilzabrutinib in the open-label period of the multicenter Phase III LUNA 3 study for adults with ITP (12:23) Romiplostim for chemotherapy-induced thrombocytopenia in patients with colorectal, gastroesophageal and pancreatic cancer: A global Phase III randomized, placebo-controlled trial (16:01) CME information and select publications
Featuring perspectives from Prof Nicoletta Colombo and Dr Kathleen N Moore, including the following topics: Introduction (0:00) Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer (2:35) Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer(41:48) CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Ovarian Cancer | Faculty Presentation 2: Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer — Nicoletta Colombo, MD CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Ovarian Cancer | Faculty Presentation 1: Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer — Angeles Alvarez Secord, MD, MHSc CME information and select publications
Download from Google Play
Download from App Store
United States
very informative, thanks 🙏
great podcast, very informative